Symbicort

How to order Symbicort

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Symbicort on Prescriptsy

Symbicort is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Symbicort is a combination inhaler containing budesonide, an inhaled corticosteroid (ICS), and formoterol fumarate dihydrate, a long-acting beta-2 agonist (LABA), delivered via the Turbohaler dry powder inhaler.

It is one of the most widely prescribed maintenance inhalers in the United Kingdom for asthma and chronic obstructive pulmonary disease (COPD).

Symbicort is available in three strengths: 100/6, 200/6, and 400/12, where the first number represents the delivered dose of budesonide in micrograms and the second represents the delivered dose of formoterol in micrograms per inhalation.

Asthma and COPD are the two most common chronic respiratory conditions in the UK, collectively affecting over 6 million people.

Effective long-term anti-inflammatory and bronchodilator therapy is the foundation of management for both conditions.

Symbicort is particularly notable in asthma management because the 200/6 strength can be used as part of the MART (Maintenance and Reliever Therapy) strategy, where a single inhaler serves as both the regular preventer and the as-needed reliever, eliminating the need for a separate short-acting bronchodilator.

This page provides a comprehensive clinical overview of Symbicort, including its mechanism of action, clinical evidence, the MART approach, dosing across indications, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Symbicort

Before reading further, note the following key safety points about Symbicort.

• If you are not on the MART regimen, Symbicort is a preventer inhaler and should not be used to relieve sudden symptoms. Always carry a separate reliever inhaler for acute breathlessness.
• If you are on the MART regimen (Symbicort 200/6 only), you may use additional puffs for symptom relief, but do not exceed 8 inhalations in total per day without seeking medical advice.
• Do not stop Symbicort suddenly. Dose reduction must be gradual and supervised by your prescriber.
• Rinse your mouth with water and spit after every inhalation to reduce the risk of oral thrush and hoarseness.

Understanding asthma and COPD

Asthma

Asthma is a chronic inflammatory condition of the airways characterised by variable airflow obstruction, bronchial hyperresponsiveness, and episodic symptoms of wheeze, breathlessness, chest tightness, and cough.

The inflammation is predominantly eosinophilic and T-helper type 2 (Th2) driven, involving mast cells, eosinophils, T lymphocytes, and structural cells.

Triggers include allergens, respiratory infections, exercise, cold air, and air pollution. The airflow limitation in asthma is largely reversible, distinguishing it from COPD.

Approximately 5.4 million people in the UK are currently receiving treatment for asthma.

COPD

Chronic obstructive pulmonary disease is characterised by persistent, progressive airflow limitation associated with chronic inflammation in the airways and lung parenchyma, most commonly caused by cigarette smoking.

COPD encompasses chronic bronchitis and emphysema. The inflammation in COPD is predominantly neutrophilic, involving macrophages and CD8+ T lymphocytes. Unlike asthma, the airflow limitation is largely irreversible.

Over 1.2 million people in the UK have a confirmed COPD diagnosis, with an estimated 2 million more undiagnosed.

How Symbicort works: dual mechanism of action

Budesonide: inhaled corticosteroid (ICS)

Budesonide is a synthetic glucocorticoid with potent local anti-inflammatory activity.

After inhalation and deposition in the airways, budesonide binds to intracellular glucocorticoid receptors in airway epithelial cells, inflammatory cells, and smooth muscle cells.

The activated receptor complex translocates to the nucleus, where it suppresses the transcription of pro-inflammatory genes (transrepression) and activates anti-inflammatory genes (transactivation).

This reduces eosinophilic infiltration, mast cell degranulation, mucus hypersecretion, and subepithelial fibrosis, collectively reducing airway inflammation and hyperresponsiveness.

Budesonide has a favourable safety profile among ICS molecules due to its high first-pass hepatic metabolism (approximately 90%), which rapidly inactivates the fraction of the dose swallowed after oropharyngeal deposition.

This results in low systemic bioavailability (approximately 10% of the delivered dose) and a reduced risk of systemic corticosteroid side effects compared with some other ICS molecules at equivalent anti-inflammatory doses.

Formoterol: long-acting beta-2 agonist (LABA)

Formoterol is a selective beta-2 adrenoceptor agonist with two distinctive pharmacological properties: a rapid onset of action (within 1 to 3 minutes, comparable to the short-acting bronchodilator salbutamol) and a long duration of action (at least 12 hours).

Stimulation of beta-2 receptors on airway smooth muscle activates adenylyl cyclase, increases intracellular cyclic AMP, and activates protein kinase A, leading to smooth muscle relaxation and bronchodilation.

Formoterol also increases mucociliary clearance and may have anti-oedema effects on the bronchial mucosa.

The rapid onset of formoterol distinguishes Symbicort from other ICS/LABA combinations such as Seretide (fluticasone/salmeterol), where the LABA (salmeterol) has a slower onset (10 to 20 minutes).

This rapid onset is the pharmacological rationale for the MART strategy, as formoterol provides quick symptom relief comparable to a SABA, while the concurrent ICS dose delivers an anti-inflammatory boost at the time symptoms indicate worsening airway inflammation.

Pharmacological synergy

ICS and LABA have complementary and synergistic mechanisms.

Corticosteroids increase the expression of beta-2 adrenoceptors on airway smooth muscle, counteracting the downregulation (desensitisation) that occurs with chronic beta-2 agonist use.

Conversely, LABAs enhance glucocorticoid receptor translocation to the nucleus, amplifying the anti-inflammatory effects of the ICS.

This mutual potentiation means that the combination is more effective than simply increasing the dose of either component alone, with a more favourable side-effect profile.

Clinical evidence for Symbicort

Symbicort MART in asthma

The MART strategy with Symbicort 200/6 has been evaluated in multiple large-scale randomised controlled trials, including STAY, COMPASS, and SMILE.

These trials consistently demonstrated that MART reduced the risk of severe asthma exacerbations by 40 to 50% compared with conventional fixed-dose ICS/LABA regimens with a separate SABA reliever.

The exacerbation reduction was achieved at lower average ICS doses, as the anti-inflammatory component is delivered on demand when symptoms indicate worsening inflammation.

The STAY study (Symbicort as maintenance and reliever therapy in mild asthma) showed that MART with low-dose Symbicort was as effective as higher-dose conventional maintenance therapy in preventing exacerbations, with the advantage of lower overall corticosteroid exposure.

The COMPASS study demonstrated that Symbicort MART was superior to fixed-dose Symbicort plus a SABA reliever in reducing severe exacerbations.

NICE guideline NG80 and BTS/SIGN guidelines recognise MART as an option from Step 3 of the asthma treatment ladder for patients using low-dose ICS/LABA maintenance therapy.

Symbicort in COPD

In COPD, Symbicort has been studied in the SUN and SHINE trials and in the PATHOS observational study.

The SUN trial demonstrated that Symbicort 400/12 twice daily reduced the rate of severe COPD exacerbations by 24% compared with formoterol alone.

The PATHOS study, a large Swedish observational study, found that budesonide/formoterol was associated with fewer severe exacerbations and pneumonia events compared with fluticasone/salmeterol.

The NICE NG115 guideline recommends ICS/LABA therapy in COPD for patients with exacerbation history and features suggesting eosinophilic inflammation, asthma-COPD overlap, or blood eosinophils at or above 300 cells per microlitre.

Where Symbicort fits in UK guidelines

Asthma (NICE NG80 and BTS/SIGN)

In the stepwise approach to asthma management, Symbicort is positioned from Step 3 onwards.

At Step 3, an ICS/LABA combination is recommended for patients whose asthma is not adequately controlled on low-dose ICS alone.

Symbicort 200/6 as MART is an option at this step. At Step 4, the ICS dose can be increased (using the 400/12 strength) or additional controllers added.

Symbicort is also used at Step 5 in combination with biological therapies for severe asthma.

COPD (NICE NG115)

In COPD, NICE recommends ICS-containing regimens only for patients with exacerbation risk and evidence of eosinophilic inflammation.

Symbicort is an appropriate choice when LAMA plus LABA therapy has not adequately controlled exacerbations in patients with raised eosinophils.

In patients without eosinophilic features, LAMA/LABA combinations without ICS are preferred to avoid the pneumonia risk associated with long-term ICS in COPD.

The Turbohaler device

The Symbicort Turbohaler is a breath-actuated dry powder inhaler (DPI) that requires no propellant.

The drug is delivered as a fine powder that is dispersed and inhaled during a deep, forceful breath.

Unlike pressurised metered-dose inhalers, there is no need to coordinate pressing a canister with inhalation.

However, adequate inspiratory flow (typically at least 30 litres per minute) is required to de-aggregate the powder particles and achieve satisfactory lung deposition.

Patients with very severe airflow limitation may not generate sufficient inspiratory flow, in which case an alternative device such as a pMDI with spacer should be considered.

The Turbohaler has a dose indicator window that shows the approximate number of doses remaining.

A red mark appears when approximately 20 doses are left, serving as a reminder to obtain a replacement. When the indicator reaches zero, the device should be discarded.

The mouthpiece should be kept dry and cleaned weekly by wiping with a dry cloth. Do not use water to clean the Turbohaler.

Side effects of Symbicort

Local side effects

Oropharyngeal candidiasis (oral thrush) and dysphonia (hoarseness) are the most common local effects and are attributable to the ICS component.

They can be minimised by mouth rinsing after inhalation and using the lowest effective ICS dose. Throat irritation and cough on inhalation may also occur.

Systemic side effects of the ICS component

At recommended doses, systemic effects of budesonide are uncommon due to high first-pass metabolism.

With prolonged high-dose use, adrenal suppression, reduced bone mineral density, growth retardation in children, posterior subcapsular cataracts, and glaucoma are possible.

Growth should be monitored in children on long-term ICS. Patients on high-dose ICS for prolonged periods should carry a steroid treatment card.

Beta-2 agonist side effects

Tremor, palpitations, headache, and muscle cramps are dose-related effects of formoterol and usually diminish with time. Tachycardia, extrasystoles, and QTc prolongation may occur at high doses. Hypokalaemia is a risk when formoterol is combined with other potassium-depleting medicines.

When to seek medical advice

Contact your GP, pharmacist, or NHS 111 if you develop persistent oral thrush, a hoarse voice that does not improve, worsening asthma or COPD symptoms, palpitations, tremor that interferes with activities, or any symptoms you think may be medication-related.

Seek emergency help (call 999 or attend A&E) if your reliever inhaler or MART extra doses do not control your symptoms, you are too breathless to speak, your lips turn blue, your heart is beating very fast or irregularly, or you experience sudden visual changes.

Report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Do not stop suddenly

Abrupt withdrawal of Symbicort may cause worsening of asthma or COPD and, in patients on high doses, adrenal insufficiency. Dose reduction should always be gradual and supervised by a clinician.

Infections

Inhaled corticosteroids may increase susceptibility to or severity of certain infections.

Patients who have not had chickenpox or measles should avoid contact with infected individuals and seek urgent medical advice if exposed.

Active pulmonary tuberculosis requires appropriate treatment before starting ICS therapy.

Cardiovascular caution

Formoterol can cause cardiovascular effects including tachycardia, palpitations, and ECG changes. Use with caution in patients with ischaemic heart disease, arrhythmias, severe hypertension, and prolonged QTc interval. Monitor serum potassium in patients at risk of hypokalaemia.

Lactose and milk protein

The Symbicort Turbohaler contains lactose monohydrate, which includes trace amounts of milk protein. Patients with known severe milk protein allergy should not use this product.

How to get a Symbicort prescription in the UK

Symbicort is a prescription-only medicine in the UK.

It is commonly prescribed by GPs, respiratory nurses, and hospital respiratory physicians for asthma (from BTS/SIGN Step 3 onwards) and for COPD in patients with appropriate clinical indications.

Repeat prescriptions can be obtained through GP surgeries or authorised online prescribers registered with the GPhC. Symbicort is available on NHS prescription.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Generic budesonide/formoterol Turbohalers are also available and may be prescribed to reduce NHS costs while delivering equivalent clinical outcomes.

Living with asthma or COPD

Using your inhaler correctly and consistently is the most important thing you can do to control your symptoms and reduce the risk of exacerbations.

In addition, keeping a written personalised asthma action plan (or COPD self-management plan) agreed with your GP or specialist nurse helps you recognise early signs of deterioration and take appropriate action.

Attending annual respiratory reviews ensures your treatment remains optimised, your inhaler technique is checked, and your lung function is monitored.

For COPD, pulmonary rehabilitation and smoking cessation are essential non-pharmacological interventions with strong evidence of benefit.

Sources

• Symbicort Turbohaler 200/6, Summary of Product Characteristics (EMC)
• Budesonide with formoterol, British National Formulary (BNF)
• NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management
• NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
• BTS/SIGN British Guideline on the Management of Asthma
• Symbicort, NHS
• MHRA Yellow Card Scheme